Up-to-date news about Intravacc
Stay informed about the latest developments in our mission to pioneer transformative vaccines with up-to-date corporate communications. Get the latest news on our development and business milestones, as well as industry insights, partnership announcements, and corporate reports.
Enabling Tech Transfer of B. pertussis OMV Technology to our Partner Chonquing Zhifei Biological Products
Intravacc publishes 2022 annual report
Looking back on a successful Bio International 2023 in Boston!
Meet the new Business Development Team
Dutch State Announces the Sale of Intravacc B.V. (The Netherlands)
CEPI partners with Intravacc to develop an intranasal, broadly protective Betacoronavirus vaccinee
Intravacc awarded US$14.6 Million NIH/NIAID contract to develop intranasal gonorrhea vaccine
Intravacc announces additional favorable preclinical and toxicology data for Avacc 10®, an intranasal SARS-CoV-2 candidate vaccine
Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant
Intravacc publishes 2021 Annual Report and announces expansion of its management team and board of directors
